Palo Alto, CA – October 1, 2024– LVIS Corporation, an innovator in neural information analysis technology, has launched NeuroMatch® Access, a cloud-based SaaS platform designed to revolutionize EEG diagnostics by streamlining review and enhancing physician collaboration. This groundbreaking platform, now available to the U.S. market, helps improve clinical workflows allowing neurologists to quickly review and interpret EEG data while collaborating in real-time to provide more accurate and timely diagnosis.
At the heart of this innovation is NeuroMatch, a cutting-edge technology that leverages artificial intelligence to review and interpret EEG signals by removing unwanted artifacts. This technology enables clinicians to visualize and understand the intricate communication pathways of brain circuits, facilitating targeted interventions and restorative strategies to enhance neurological health.
“NeuroMatch represents a transformative step towards democratizing neurological care for patients worldwide,” said Dr. Jin Hyung Lee, Founder of LVIS Corporation and Associate Professor at Stanford University, where she leads the Lee Lab focused on brain function restoration.“Our commitment is to harness advanced technology to not only expedite EEG diagnostics but also to make these critical services accessible to all, ensuring that every patient receives the timely and effective care they deserve.”
A first-generation immigrant, Dr. Lee was inspired to study the brain after losing her grandmother to stroke, and she has dedicated over a decade to developing NeuroMatch, earning numerous awards in the process, including the NIH Director’s Pioneer Award (2019), NIH Director’s New Innovator Award (2010), NSF CAREER Award (2011), and the IEEE EMBS BRAIN Grand Challenge Award (2022). Currently, NeuroMatch Access is fully operational for clinical EEG review.
LVIS successfully launched NeuroMatch in South Korea earlier this year, installing the technology in 10 of the country’s top hospitals, recognized as leaders in healthcare, advanced medical services and research. The company also launched their first NeuroMatch Center in Daegu, South Korea, to serve as an educational hub. The Center provides monitoring rooms for EEG diagnostics and a lecture hall for training healthcare professionals.
LVIS has secured key regulatory approvals for NeuroMatch, including first US FDA clearance in June 2023. Available to neurologists, hospitals, and clinics, NeuroMatch Access provides a scalable, cost-effective solution to modernize diagnostic capabilities and enhance patient care. For more information or to schedule a demonstration, visit https://lviscorp.com/.
About LVIS Corporation:
LVIS Corporation, headquartered in Palo Alto, California, is a pioneer in the field of neurotechnology. The company’s mission is to improve patient care through innovative technological solutions. With a team of leading experts in neurology, AI, and bioengineering, LVIS is dedicated to pushing the boundaries of what is possible in neurological diagnostics and treatment.
Media Contact:
Amanda Gort, Public Relations Specialist
KCOMM for LVIS Corporation
amanda@kcomm.com (949) 443-9300